For Immediate Release
Chicago, IL – May 9, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Verizon (VZ - Free Report) , Abbott (ABT - Free Report) , Illinois Tool Works (ITW - Free Report) , Moody's (MCO - Free Report) and Baker Hughes .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Verizon, Abbott Labs and Illinois Tool Works
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Verizon, Abbott and Illinois Tool Works. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Verizon’s shares have gained +22.1% in the past year, outperforming the Zacks Wireless National industry’s increase of +10.2% during the same period. Verizon started 2019 on a promising note with solid performance in the first quarter, primarily backed by the wireless business.
The company recorded modest top-line growth and remains well poised to benefit from the impending 5G boom. The Zacks analyst thinks focus on online content delivery, mobile video and online advertising are likely to stoke further growth. Management also raised its earlier guidance on underlying strength of its business model.
However, Verizon continues to struggle in a competitive and saturated U.S. wireless market, where spectrum crunch has become a major issue. The wireline division is struggling with persistent losses in access lines owing to competitive pressure from VoIP service providers and aggressive triple-play offerings by cable firms. Verizon is also spending heavily on promotion and lucrative discounts to woo customers, which is also weighing on margins.
Shares of Abbott have gained +29.5% over the past year, outperforming the Zacks Medical Products industry, which has increased +5.9% over the same period. Abbott exited first quarter 2019 with better-than-expected earnings and revenues figures.
The Zacks analyst likes the strong and consistent performance by the company’s EPD and Medical Devices segments on an organic basis. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip has improved further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. Abbott's emerging market performance has been promising. On the flip side, sluggish Rhythm Management arm in the United States continues to dent growth. Increasing currency headwinds to some extent dented Abbott’s international performance in the last-reported quarter.
Illinois Tool Works’ shares have outperformed the Zacks Industrial Machinery industry over the past six months, gaining +14.4% over the period versus the industry’s +10.3% increase. The Zacks analyst thinks Illinois Tool will gain from a diversified business structure, policy of rewarding shareholders handsomely, enterprise initiatives and skilled management team.
In first-quarter 2019, the company's earnings surpassed estimates but declined year over year due to weak sales, higher taxes, forex woes and restructuring costs. For 2019, it anticipates earnings per share to increase 4-8% year over year. Enterprise Strategy is anticipated to boost margins by 100 basis points (bps). Share buybacks are likely to amount to $1.5 billion.
However, organic sales are predicted to increase 0.5-2.5%, down from previously mentioned 1-3%. Also, high tax rate and unfavorable foreign exchange (that will lower earnings by 6 cents in the second quarter) remain concerns. Earnings estimates for 2019 have declined in the past 30 days.
Other noteworthy reports we are featuring today include Moody's and Baker Hughes.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.